Physicochemical Properties
| Molecular Formula | C34H49F3O4 |
| Molecular Weight | 578.75 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Caspase-3 Bcl-2 Bcl-xL |
| ln Vitro | Anticancer agent 201 (Compound 2f) (3.5 μM, 17.5 μM; 24 hours) can significantly induce cytotoxicity, increase the number of apoptotic cells, and cause a dose-dependent decrease in the mitochondrial membrane potential of CCRF-CEM cells[1]. Anticancer agent 201 (3.5 μM, 17.5 μM; 24 hours) blocks or slows down the cell cycle in the G0/G1 phase, reduces the proportion of cells in the S phase, and inhibits RNA synthesis in CCRF-CEM cells[1]. Cytotoxic activity of anticancer agent 201 against 8 tumor (including multidrug-resistant variants) and 2 normal fibroblast cell lines[1] Cell lines CCRF-CEM CEM-DNR K562 K562-TAX A549 HCT116 HCT116p53-/- U20S BJ MRC-5 IC50 (μM) 3.5 4.9 23 17 11 10 18 19 ＞50 27 Apoptosis Analysis[1] Cell Line: CCRF-CEM cancer cell line Concentration: 3.5 μM, 17.5 μM Incubation Time: 24h Result: Induced the strongest cytotoxic reaction and the number of apoptotic cells increased significantly. Resulted in a significant decrease in mitochondrial membrane potential of CCRF-CEM cells in a dose-dependent manner. Cell Cycle Analysis[1] Cell Line: CCRF-CEM cancer cell line Concentration: 3.5 μM, 17.5 μM Incubation Time: 24h Result: Caused the cell cycle to be blocked or slowed down in the G0/G1 phase, while the proportion of S phase cells decreases. At 17.5 μM, the mitosis rate of the cells decreased. At 3.5 μM increased the proportion of BRDU-positive cells. At 17.5μM, the proportion of BRDU- positive cells decreased. At 17.5μM, RNA synthesis almost completely stopped. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: CCRF-CEM cancer cell line Concentration: 3.5 μM, 17.5 μM Incubation Duration: 24h Experimental Results: Leaded to decreased expression of both Bcl-2 and Bcl-XL. At 17.5μM, caused the activation of caspase-3 and the cleavage of PARP. |
| References |
[1]. Novel triterpenoid pyrones, phthalimides and phthalates are selectively cytotoxic in CCRF-CEM cancer cells - Synthesis, potency, and mitochondrial mechanism of action. Eur J Med Chem. 2024;269:116336. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7279 mL | 8.6393 mL | 17.2786 mL | |
| 5 mM | 0.3456 mL | 1.7279 mL | 3.4557 mL | |
| 10 mM | 0.1728 mL | 0.8639 mL | 1.7279 mL |